An early SITC loser: Five Prime shares crushed as analysts fret over a snapshot on lead drug data
Shares of Five Prime Therapeutics $FPRX were crushed on Tuesday as word spread about their abstract released ahead of the Society for Immunotherapy of Cancer …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.